Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence (NCT05952934)
A Phase II Clinical Trial of Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the placebo arm. The ratio of the number of subjects who will receive Candin versus placebo will be 3:1. Up to 100 subjects will be screened until 80 subjects are eligible for injection.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group, PA — Fayetteville, Arkansas
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Highlands Oncology Group, PA — Fayetteville, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Highlands Oncology Group, PA — Rogers, Arkansas
- Highlands Oncology Group, PA — Springdale, Arkansas
- Perlmutter Cancer Center at NYU Langone Health — Mineola, New York
- Perlmutter Cancer Center at NYU Langone Health — New York, New York
📞 Contact the Study Coordinator
Phone: (501) 686-8274
Email: MTrujillo@uams.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab Plus Olaparib in LA-HNSCC — Indianapolis, Indiana
- TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC — Tampa, Florida
- HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer — Dallas, Texas
- MicroRNA Markers in Head and Neck Cancers — Aurora, Colorado
- A Clinical Trial Evaluating TG4050 in Head and Neck Cancer — Jacksonville, Florida
- A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer — La Jolla, California
Explore by condition: All Squamous Cell Carcinoma of Head and Neck clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.